Barinthus Biotherapeutics (BRNS) Income from Non-Controlling Interests (2020 - 2026)
Barinthus Biotherapeutics (BRNS) reported Income from Non-Controlling Interests of -$3000.0 for Q1 2026, up 70.0% on a YoY basis from -$1764.7 in Q1 2025, and up 75.0% quarter-over-quarter from -$12000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics has reported Income from Non-Controlling Interests for 7 years, with the latest figure at -$3000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests rose 70.0% year-over-year to -$3000.0; the trailing twelve-month figure through Mar 2026 stood at -$15000.0 (up 82.76% YoY), and the FY2025 full-year result was -$22000.0, up 79.82% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$3000.0, up from -$12000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $26000.0 in Q4 2022, with the low at -$51000.0 in Q4 2024.
- Historically, Income from Non-Controlling Interests has averaged -$15176.5 across 5 years, with a median of -$12000.0 in 2025.
- Annual changes were most pronounced in 2024 — Income from Non-Controlling Interests plunged 950.0% — and 2025, when it soared 145.45%.
- Barinthus Biotherapeutics' Income from Non-Controlling Interests stood at $26000.0 in 2022, then slumped by 76.92% to $6000.0 in 2023, then sank by 950.0% to -$51000.0 in 2024, then soared by 76.47% to -$12000.0 in 2025, then jumped by 75.0% to -$3000.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$3000.0 (Q1 2026), -$12000.0 (Q4 2025), and -$5000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Barinthus Biotherapeutics | 27.57 Mn | -39.54 Mn | - | -3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,000.00 |
| Dec 31, 2025 | -12,000.00 |
| Sep 30, 2025 | -5,000.00 |
| Jun 30, 2025 | 5,000.00 |
| Mar 31, 2025 | -10,000.00 |
| Dec 31, 2024 | -51,000.00 |
| Sep 30, 2024 | -15,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Mar 31, 2024 | -28,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | -48,000.00 |
| Jun 30, 2023 | -22,000.00 |
| Mar 31, 2023 | -43,000.00 |
| Dec 31, 2022 | 26,000.00 |
| Sep 30, 2022 | -21,000.00 |
| Jun 30, 2022 | -4,000.00 |
| Mar 31, 2022 | -22,000.00 |
| Dec 31, 2021 | -58,000.00 |
| Sep 30, 2021 | -13,000.00 |
| Jun 30, 2021 | -58,000.00 |